The goal of this program is to answer the fundamental scientific questions for the development of an effective approach to delivering radiation therapy to cancer on antibody-based radiopharmaceuticals. These basic questions refer to the choice of antibody fragments related to their biokinetics, the variation of the biokinetics with variations in the radiochemistry of labeling and the radionuclide used to label, the radionuclide radiation dosimetry, and the feasibility calculated from quantitative imaging in patients and implementation of a proven kinetic model. To approach these problems this program has five discrete, but interrelated aims. Radionuclide choices for effective therapy for solid tumors and bone marrow infiltrating tumor cells; The development of radiochemistry to optimize tumor uptake and increase non-target tissue clearance of the radiopharmaceuticals; Further development and documentation of the peri-fusion system for screening antibodies for human tumor uptake, normal tissue cross-reactivity, and tissue stability of new antibody radiometal linkages; Quantitation in vivo of pharmacokinetics and radiation dosimetry for radioiodinated and radiometal chelate-labeled antibodies and fragments; and Verification of dosimetry predictions and therapy feasibility in patients using selected I-131 and Cu-67 radioimmunopharmaceuticals.

Viewgraph comprise the report. Aspects of design which are discussed are: end cell coil arrangement, neutral beam and rf injection, load definition on end cell coils, and intracoil structure for all coils. (WRF)

A weekly publication, the Texas Register serves as the journal of state agency rulemaking for Texas. Information published in the Texas Register includes proposed, adopted, withdrawn and emergency rule actions, notices of state agency review of agency rules, governor's appointments, attorney general opinions, and miscellaneous documents such as requests for proposals. After adoption, these rulemaking actions are codified into the Texas Administrative Code.

None

The goal of this program is to answer the fundamental scientific questions for the development of an effective approach to delivering radiation therapy to cancer on antibody-based radiopharmaceuticals. These basic questions refer to the choice of antibody fragments related to their biokinetics, the variation of the biokinetics with variations in the radiochemistry of labeling and the radionuclide used to label, the radionuclide radiation dosimetry, and the feasibility calculated from quantitative imaging in patients and implementation of a proven kinetic model. To approach these problems this program has five discrete, but interrelated aims. Radionuclide choices for effective therapy for solid tumors and bone marrow infiltrating tumor cells; The development of radiochemistry to optimize tumor uptake and increase non-target tissue clearance of the radiopharmaceuticals; Further development and documentation of the peri-fusion system for screening antibodies for human tumor uptake, normal tissue cross-reactivity, and tissue stability of new antibody radiometal linkages; Quantitation in vivo of pharmacokinetics and radiation dosimetry for radioiodinated and radiometal chelate-labeled antibodies and fragments; and Verification of dosimetry predictions and therapy feasibility in patients using selected I-131 and Cu-67 radioimmunopharmaceuticals.

During radiographic experiments involving explosives, it is valuable to have a method of monitoring the x-ray flux ratio between the dynamic experiment and an x-ray taken of a static object for comparison. The standard method of monitoring with thermoluminescent detectors suffers the disadvantages of being sensitive to temperature, shock, uv radiation, cleanliness and saturation. A flux monitoring system is being studied which is not subject to any of the above disadvantages and is based upon the 63Cu(photon,n)62Cu reaction. The 62Cu has a 10 min half life and is counted by a nuclear pulse counting system within a few minutes of an explosive test. 170 microcoulomb of 19.3 MeV electrons hitting 1.18 mm of Ta produces x-rays which illuminate a 0.8mm thick by 1.6 cm diameter Cu disk placed 46 cm from the Ta. The activated Cu is placed in a counting system with a window between 400 to 600 keV and produces about 42,500 counts in the first 100 sec. counting period. Less than 0.2% of the initial activity is due to other reactions. Photo-induced neutrons in Be parts of the system are shown to produce a negligible effect in the Cu. The main disadvantage of the Cu activation is …

At Livermore we are interested in imaging the thermonuclear burn region of fusion targets irradiated at our Nova laser facility. We expect compressed core diameters to be 10's of microns, and would like images with better than 10-..mu..m resolution. Alpha particle images provided the first direct information about the thermonuclear burn geometry in thin walled exploding pusher targets. In future high density target experiments, only highly penetrating radiations like the 14-MeV neutrons will escape the target core to provide information about the burn region. To make the measurement with a neutron ''pinhole'' camera requires a 10..mu..m pinhole through about 10 cm of material and 10/sup 14/ to 10/sup 15/ source neutrons. Penumbral imaging offers some improvement over a pinhole. Zone plate coded imaging (ZPCI) techniques are particularly well suited for imaging small objects like the compressed core of a laser fusion target. We have been using ZPCI techniques to image nonpenetrating radiations like x rays and alpha particles for about 10 years. The techniques are well developed. Imaging penetrating radiations like 14-MeV neutrons using ZPCI techniques has several possible advantages. The large solid angle subtended by the Zone plate might substantially reduce the required target neutron yield needed to produce …